Literature DB >> 14739722

Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

Antonio H Madrid1, Carlos Escobar, José María G Rebollo, Irene Marín, Enrique Bernal, Sebastián Nannini, Lilianna Limón, Jian Peng, Concepción Moro.   

Abstract

Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke and mortality. The early appearance of electrical remodeling is followed by structural remodeling of the atrial tissue. Direct current cardioversion of persistent AF is the most effective treatment for the restoration of sinus rhythm, but it is hampered by a high percentage of recurrences. Recurrences may be the consequence of both electrical and structural remodeling. A study on the use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent AF showed that this angiotensin II receptor blocker combined with amiodarone prolonged sinus rhythm after cardioversion. Irbesartan may have antifibrotic effects due not only to the ability to diminish the synthesis of collagen type I molecules but also to its capacity to stimulate the degradation of collagen type I fibers, as has been demonstrated with losartan, another angiotensin II receptor blocker. This suggests that efforts to reduce the structural changes that occur during AF may be more useful in preventing recurrences than efforts designed to minimize the electrical changes alone. The AFFIRM trial compared two approaches to the treatment of AF: cardioversion with antiarrhythmic drugs to maintain sinus rhythm and the use of rate-controlling drugs. The results show that management of AF with the rhythm-control strategy offers no survival advantage over the rate-control strategy. However, non-antiarrhythmic drugs to prevent recurrences, like irbesartan, were not controlled and amiodarone was used in a low percentage of the patients. The treatment strategies proposed in both AFFIRM and RACE, in our opinion, may not be the optimal. The modern clinical approach to AF involves an early intervention to restore sinus rhythm, therefore preventing atrial remodeling. The pretreatment of patients with AF who undergo electrical cardioversion is very important and will be the subject for continuous improvement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14739722     DOI: 10.1023/B:CEPR.0000012391.95928.d2

Source DB:  PubMed          Journal:  Card Electrophysiol Rev        ISSN: 1385-2264


  4 in total

1.  Cardiac fibrosis as a determinant of ventricular tachyarrhythmias.

Authors:  Norishige Morita; William J Mandel; Yoshinori Kobayashi; Hrayr S Karagueuzian
Journal:  J Arrhythm       Date:  2014-12-01

2.  Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy?

Authors:  Hrayr S Karagueuzian
Journal:  Am J Cardiovasc Dis       Date:  2011-06-12

3.  Pharmacological management of atrial fibrillation: one, none, one hundred thousand.

Authors:  Fabiana Lucà; Mark La Meir; Carmelo Massimiliano Rao; Orlando Parise; Ludovico Vasquez; Rocco Carella; Roberto Lorusso; Benedetto Daniela; Jos Maessen; Gian Franco Gensini; Sandro Gelsomino
Journal:  Cardiol Res Pract       Date:  2011-04-26       Impact factor: 1.866

Review 4.  Anti-arrhythmic properties of non-antiarrhythmic medications.

Authors:  Emmanuel Ato Williams; Vincenzo Russo; Sergio Ceraso; Dhiraj Gupta; Richard Barrett-Jolley
Journal:  Pharmacol Res       Date:  2020-03-23       Impact factor: 7.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.